Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium acetate; water for injections - tramadol sandoz injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - reteplase -

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - voriconazole 200mg - powder for injection - 200 mg - active: voriconazole 200mg excipient: sulfobutyl betadex sodium water for injection - voriconazole - aft is indicated for the following fungal infections: invasive aspergillosis serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia) serious fungal infections caused by scedosporium spp and fusarium spp other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; iron oxide yellow; iron oxide red; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 3 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - voriconazole 200mg;  ;   - powder for injection - 200 mg - active: voriconazole 200mg     excipient: sulfobutyl betadex sodium water for injection - vfend is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida sp. infections (including c. krusei), including oesophageal and systemic candida sp. infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

neo health (nz) limited - voriconazole 200mg - powder for injection - 200 mg - active: voriconazole 200mg excipient: hydrochloric acid hydroxypropyl-beta-cyclodextrin sodium chloride water for injection - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

devatis limited - tenoxicam 20mg (+10% overage) - powder for injection - 20 mg - active: tenoxicam 20mg (+10% overage) excipient: ascorbic acid disodium edetate hydrochloric acid mannitol sodium hydroxide trometamol - tenoxicam devatis is indicated in adults for the symptomatic treatment of the following painful inflammatory and degenerative disorders of the musculoskeletal system: - rheumatoid arthritis; - osteoarthritis; - arthrosis; -ankylosing spondylitis; - extra-articular disorders, e.g. tendinitis, bursitis, periarthritis of shoulders (shoulder-hand syndrome) or hips, strains and sprains; - post-operative pain.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; erythrosine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg   potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg   excipient: colloidal silicon dioxide dimeticone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose opadry white oy-s-7300 as an alternative source of film coat sodium starch glycolate titanium dioxide - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.